PCV83 - KEY MODEL PARAMETERS AND METHODOLOGIES USED IN COST-EFFECTIVENESS ANALYSIS EVALUATING TREATMENTS FOR SECONDARY PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION (MI) OR ACUTE CORONARY SYNDROME (ACS)

Major Adverse Cardiovascular Events ◽

Model Parameters ◽

Coronary Syndrome ◽

Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin in the Secondary Prevention of Acute Coronary Syndrome

PharmacoEconomics ◽

10.2165/00019053-200220140-00003 ◽

2002 ◽

Vol 20 (14) ◽

pp. 979-987 ◽

Cited By ~ 7

Author(s):

Max Brosa ◽

Carlos Rubio-Terr??s ◽

Ibrahim Farr ◽

Vijay Nadipelli ◽

Jenaro Froufe

Keyword(s):

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Secondary Prevention ◽

Unfractionated Heparin ◽

Coronary Syndrome ◽

Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis

Value in Health ◽

10.1016/j.jval.2010.11.012 ◽

2011 ◽

Vol 14 (4) ◽

pp. 483-491 ◽

Cited By ~ 32

Author(s):

Daniel J. Crespin ◽

Jerome J. Federspiel ◽

Andrea K. Biddle ◽

Daniel E. Jonas ◽

Joseph S. Rossi

Keyword(s):

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Secondary Prevention ◽

Antiplatelet Therapy ◽

Coronary Syndrome ◽

CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis

Cardiovascular Drugs and Therapy ◽

10.1007/s10557-016-6705-y ◽

2016 ◽

Vol 31 (1) ◽

pp. 39-49 ◽

Cited By ~ 12

Author(s):

Minghuan Jiang ◽

Joyce H. S. You

Keyword(s):

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Antiplatelet Therapy ◽

Coronary Syndrome ◽

Ticagrelor Treatment for Prevention of Cardiovascular Events in High Risk Post Myocardial Infarction Patients: Cost-Effectiveness Analysis Using Evidence From The Pegasus-Timi 54 Trial

Value in Health ◽

10.1016/j.jval.2016.09.1775 ◽

2016 ◽

Vol 19 (7) ◽

pp. A655

Author(s):

P Moore ◽

A Briggs ◽

A Davies ◽

M Sculpher ◽

K Kun ◽

...

Keyword(s):

Myocardial Infarction ◽

Cost Effectiveness ◽

High Risk ◽

Cardiovascular Events ◽

Post Myocardial Infarction ◽

Pre-hospital ECG for acute coronary syndrome in urban India: A cost-effectiveness analysis

BMC Cardiovascular Disorders ◽

10.1186/1471-2261-10-13 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 9

Author(s):

Joshua Schulman-Marcus ◽

Dorairaj Prabhakaran ◽

Thomas A Gaziano

Keyword(s):

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Coronary Syndrome ◽

Effectiveness Analysis ◽

Urban India

PCV72 Long-Term Cost Effectiveness Analysis of Ticagrelor in Patients with Acute Coronary Syndrome from a Polish Health Care Perspective

Value in Health ◽

10.1016/j.jval.2011.08.792 ◽

2011 ◽

Vol 14 (7) ◽

pp. A377 ◽

Cited By ~ 2

Author(s):

T. Macioch ◽

M. Niewada ◽

P. Perkowski ◽

C. Mellström ◽

A. Budaj

Keyword(s):

Health Care ◽

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Coronary Syndrome ◽

Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome

Clinical Cardiology ◽

10.1002/clc.22756 ◽

2017 ◽

Vol 40 (10) ◽

pp. 789-796 ◽

Cited By ~ 4

Author(s):

Minghuan Jiang ◽

Joyce H.S. You

Keyword(s):

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Antiplatelet Therapy ◽

Dual Antiplatelet Therapy ◽

Drug Eluting Stents ◽

Coronary Syndrome ◽

Effectiveness Analysis ◽

Drug Eluting

Clopidogrel Versus Aspirin For The Treatment Of Acute Coronary Syndrome After A 12-Month Dual Antiplatelet Therapy: A Cost-Effectiveness Analysis From China Payer’s Perspective

Value in Health ◽

10.1016/j.jval.2018.04.364 ◽

2018 ◽

Vol 21 ◽

pp. S60

Author(s):

L Zhang ◽

Z Lin ◽

H Yin ◽

J Liu ◽

J Xuan

Keyword(s):

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Antiplatelet Therapy ◽

Dual Antiplatelet Therapy ◽

Coronary Syndrome ◽

CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Value in Health ◽

10.1016/j.jval.2018.09.032 ◽

2018 ◽

Vol 21 ◽

pp. S6

Author(s):

O. Dong ◽

C.R. Lee ◽

S.B. Wheeler ◽

D. Voora ◽

S.B. Dusetzina ◽

...

Keyword(s):

Percutaneous Coronary Intervention ◽

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Coronary Intervention ◽

Pharmacogenetic Testing ◽

Coronary Syndrome ◽

Effectiveness Analysis ◽

Percutaneous Coronary

CV5 SHORT AND LONG TERM COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT S T-SEGMENT ELEVATION (ACS) IN SCANDINAVIAN COUNTRIES

Value in Health ◽

10.1016/s1098-3015(10)61595-1 ◽

2003 ◽

Vol 6 (6) ◽

pp. 621 ◽

Cited By ~ 7

Author(s):

P Lindgren ◽

B Jönsson ◽

J Spiesser ◽

P Carita ◽

S Gabriel

Keyword(s):

Acute Coronary Syndrome ◽

Cost Effectiveness ◽

Coronary Syndrome ◽

Effectiveness Analysis ◽

Short And Long Term